Navigation Links
Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
Date:2/19/2008

- Establishes Plan for Biomarker Study -

MONTVALE, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced that it plans to conduct a clinical study of MEM 3454, the Company's lead nicotinic alpha-7 partial agonist, on two biomarkers of schizophrenia, P50 sensory gating and mismatch negativity, in patients with schizophrenia. The biomarker study, and additional formulation and manufacturing activities for MEM 3454, will be funded by Roche, under the companies' collaboration for the development of nicotinic alpha-7 receptor agonists.

"This new study will greatly enhance our ability to measure and predict the efficacy of MEM 3454 and other compounds in the nicotinic alpha-7 receptor program," said Stephen Murray, MD, Ph.D, Chief Medical Officer of Memory Pharmaceuticals Corp. "The study should be underway this summer with data available by early 2009. The biomarker data, together with the results of our ongoing Phase 2a study in CIAS, will help with the design of later-stage trials in schizophrenia."

The biomarker study will enroll approximately 12 patients with stable schizophrenia who are receiving atypical antipsychotic therapy. Subjects will be randomized to receive MEM 3454 and placebo in a 5-way cross-over design. Each subject will participate in 5 treatment periods. During each period, subjects will receive single doses of 1 mg, 5 mg, 15 mg, or 50 mg of MEM 3454 or placebo, with a 4-day wash-out period between each treatment period. The primary objective of the trial is to study P50 sensory gating and mismatch negativity as potential efficacy biomarkers for nicotinic alpha-7 agonists, such as MEM 3454, in schizophrenia. P50 sensory gating and mismatch nega
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
2. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
3. Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease
4. Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014  CryoLife, Inc. (NYSE: CRY ... focused on cardiac and vascular surgery, announced today that ... Executive Officer, has been elected to the Company,s Board ... Steven G. Anderson , Executive Chairman of CryoLife, stated, "Since ... be an excellent leader who is well positioned to ...
(Date:10/22/2014)... Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the second fiscal quarter ended September ... Revenues of $53.9 million, up 18% over last year,s ... 33% over last year,s comparable quarter. Revenues ... Laboratories (AVRL) of $3.5 million, up 50% over last ...
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, ... Online, complimentary registration available at: http://bit.ly/1yStiU9 ... Archana Vidyasekar and Visionary Innovation Research Group ... wireless electricity, self-assembling materials, nanobots and flexible ... which will transform our lives in the ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4
... YORK, Feb. 16, 2011 Get content from ... The European Parliament is expected ... prevent falsified medicines from entering the legal distribution ... packages have reached patients in the last years. ...
... MedAptus®, the market leader for charge capture technologies, ... has selected the company,s Professional Intelligent Charge Capture ... hospitalist team, comprised of both physicians and nurse ... web as well as iPhone® and BlackBerry® devices. ...
Cached Medicine Technology:Hospitalists at New England Baptist Hospital Choose MedAptus 2
(Date:10/20/2014)... 20, 2014 With a mere 19 ... Crist made a brief fundraising stop at the ... , Fresh from a debate last night with his ... stage for the first seven minutes because Crist had ... described the incident in one word: "weird." , Before ...
(Date:10/20/2014)... MA (PRWEB) October 20, 2014 ... sponsoring a booth at the American Foundation for Suicide ... 25th. The AFSP is a not-for-profit organization that hosts ... Net proceeds from these events are used to help ... but education and personal relationships as well. , ...
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, ... Columbus, Inc., A Division of MaternOhio Clinical Associates, Inc., ... 100,000 patients annually. Dr. Murphy will provide a full ... a women’s life. She is accepting new patients at ... Dublin. , Dr. Murphy offers a wide variety of ...
(Date:10/20/2014)... 2014 hc1.com today announced the ... solution that enables healthcare organizations of all sizes ... customer relationship management (“CRM”) solution. , Designed from ... of the healthcare industry, the hc1 Healthcare Relationship ... patients by combining healthcare CRM, HIPAA-compliant collaboration, and ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 JZ Fitness, ... nutritional coaching, corporate wellness programming, authorship, international lecturing and ... excited to announce the release of the JZ Fitness ... many years of coaching thousands of individuals on nutrition, ... app that does not require calorie counting or cumbersome ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3
... World Health Organization to investigate the possibility of building the ... They are already ready to invest $1.9bn from various developed ... being done. ,Tony Blair while facing questions in ... outbreak of bird flu insisted that precautions were adequate. He ...
... at the University of California, Irvine (UCI) and also ... experimental drug// AF267B is effective against both forms of ... ,This compound (AF267B) curbs both the amyloid protein ... another lesion, the tangles of protein called tau. ...
... of Reading in England, has said that a strong link ... cancer. She says that he aluminum-based active ingredient used in ... exposure to estrogen is the risk factor which is tied ... salts in antiperspirants enter the body and mimic estrogen it ...
... people in the steel town were affected by a mysterious viral ... group at a slum// cluster in Panposh on the outskirts of ... rapidly spread to other parts of the town. ,The ... said a senior district health official. ,Most of the ...
... now established that a delayed-release stimulant, used for treatment ... less abuse, when compared to other stimulant drugs//. Therapeutic ... oral formulation have not been reported to produce subjective ... of the study can be found in the American ...
... half full glass, there is some hearty news for you. The ... lower cardiovascular risk by 50%. ,In a study conducted ... 84, the most optimistic had a lower risk of cardiovascular death. ... years. This study has been published in the Archives of Internal ...
Cached Medicine News:Health News:Experimental Alzheimer’s Drug curbs the disease in mic 2Health News:Concerta, Drug Used in ADHD Treatment Less Likely To Result In Abuse 2
... The Dual Media Set, different from ... Broth (LB) or other specially prepared medium, ... OVEREXPRESSION BROTH (OB). For cell expansion, E. ... the production of the recombinant protein is ...
...
0.3% Beef extract, 0.5% Peptone, 0.5 % Lactose....
... controls the temperature at your lab bench. This ... to 99 C*, with the "plus" being a ... C. The thermoblocks for 0.2 ml**, 0.5 ml, ... a high degree of flexibility for a multitude ...
Medicine Products: